CMB Stock News Of The Day 📰🗞️🗞️📈📉

“Amazon Pharmacy Expands Into Weight-Loss Drug Delivery With Novo Nordisk Partnership” 🚨🚨🚨

Amazon Pharmacy announced Friday that it will begin offering home delivery of Novo Nordisk’s newly approved Wegovy weight-loss pill, marking a major step in the evolution of direct-to-consumer healthcare. The move strengthens Amazon’s growing presence in pharmaceuticals while giving Novo another powerful distribution channel as competition in the obesity-drug market intensifies.

The Wegovy pill will be available through insurance as well as cash-pay options, with Novo setting a $149 monthly cash price — less than half the cost of its injectable weight-loss treatments sold through the same channel. The lower price point could significantly broaden access and attract patients seeking alternatives to injections.

Amazon joins a growing network of distributors for the pill, including Costco and Walmart, along with major telehealth platforms such as Ro, Weight Watchers, and LifeMD. The expanded distribution strategy comes as Novo Nordisk works to regain market share after Eli Lilly overtook it, largely due to Lilly’s earlier focus on direct-to-consumer availability.

The FDA approved Novo’s oral weight-loss pill in December, making it the first weight-loss pill approved for the U.S. market. The drug contains semaglutide, the same active ingredient used in Novo’s blockbuster injectables Ozempic and Wegovy. Meanwhile, Eli Lilly’s competing oral treatment, orforglipron, is expected to launch later this year, setting the stage for heightened competition across pharma, retail, and digital health platforms.